Company intelligence / Profile preview

Emmetrope Ophthalmics LLC

Menlo Park, California, United Statesemmecell.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Emmetrope Ophthalmics has advanced its lead candidate EO2002—a first-in-class, non-surgical magnetic cell-based therapy—into Phase 1 clinical trials for corneal edema. Early preclinical and initial human data have shown strong safety and efficacy profiles. The company’s approach aims to provide minimally invasive alternatives to corneal transplantation by repopulating dysfunctional endothelial cells using their proprietary MCD platform.[5]

Therapeutic areas: Ophthalmology
Modalities: Cell therapy (magnetic cell-based therapies)Magnetic nanoparticle-enabled delivery
Industry: Biotech

Drug pipeline

3 assets

EO2002

2 more assets in the full pipeline.

Request access →

Partnerships

Eversight

Beyond the preview

Go deeper on Emmetrope Ophthalmics LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emmetrope Ophthalmics LLC.

Explore the full profile